Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore Technologies Expects 2022 Revenue to Rise 49 Percent

NEW YORK – Oxford Nanopore Technologies said on Tuesday that it expects its 2022 revenue to rise 49 percent year over year.

For the year ended Dec. 31, the firm expects total revenue of approximately £199.0 million ($243.9 million), including non-recurring revenue of £51.8 million from the company’s now-concluded COVID-19 testing contract with the Department of Health and Social Care. This represents a 49 percent increase from 2021, when total revenue was £133.7 million.

The company’s 2022 life science research tools revenue is expected to be roughly £147.0 million, a 16 percent increase from £127.0 million in 2021 and in line with the firm's guidance of £145.0 million to £160.0 million.

"Oxford Nanopore continues to demonstrate strength and resilience with strong core revenues driven by growth across all customer groups in 2022," Oxford Nanopore CEO Gordon Sanghera said in a statement. "With a single high-performance technology for all users' sequencing needs, we enter 2023 with good momentum as we continue to invest in our operational expansion alongside our innovation."

The company said it plans to report its 2022 earnings on March 21, followed by its annual report.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.